Werewolf Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 14

Employees

  • Stock Symbol
  • HOWL

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.94
  • (As of Friday Closing)

Werewolf Therapeutics General Information

Description

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 300 Wyman Street
  • Suite 300
  • Waltham, MA 02451
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 300 Wyman Street
  • Suite 300
  • Waltham, MA 02451
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Werewolf Therapeutics Stock Performance

As of 20-Nov-2026, Werewolf Therapeutics’s stock price is $0.94. Its current market cap is $46M with 48.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.94 $0.99 $0.27 - $1.20 $46M 48.6M 5.63M -$0.58

Werewolf Therapeutics Financials Summary

As of 30-Sep-2026, Werewolf Therapeutics has a trailing 12-month revenue of $21M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 22,838 2,339 (20,096) 61,832
Revenue 21,000 0 1,885 19,943
EBITDA (21,852) (57,022) (70,718) (39,881)
Net Income (28,120) (60,822) (70,515) (37,368)
Total Assets 42,753 69,396 126,929 174,833
Total Debt 0 37,671 37,087 51,923
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Werewolf Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Werewolf Therapeutics‘s full profile, request access.

Request a free trial

Werewolf Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Werewolf Therapeutics‘s full profile, request access.

Request a free trial

Werewolf Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimul
Drug Discovery
Waltham, MA
14 As of 2026

Princeton, NJ
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Werewolf Therapeutics Competitors (6)

One of Werewolf Therapeutics’s 6 competitors is PMV Pharma, a Formerly VC-backed company based in Princeton, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PMV Pharma Formerly VC-backed Princeton, NJ
Xilio Therapeutics Formerly VC-backed Waltham, MA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
Nektar Therapeutics Formerly VC-backed San Francisco, CA
Centrose Venture Capital-Backed Madison, WI
To view Werewolf Therapeutics’s complete competitors history, request access »

Werewolf Therapeutics Patents

Werewolf Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026072455-A1 Single domain human serum albumin antibodies Pending 26-Sep-2024
WO-2026006413-A1 Il-12 prodrugs, methods of use and pharmaceutical compositions Pending 25-Jun-2024
WO-2025250977-A1 Cancer therapy using il-2 prodrug Pending 31-May-2024
WO-2025240781-A2 Modified antibodies and immunoglobulin formats Pending 15-May-2024
WO-2025240781-A3 Modified antibodies and immunoglobulin formats Pending 15-May-2024 C07K16/2809
To view Werewolf Therapeutics’s complete patent history, request access »

Werewolf Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Werewolf Therapeutics Acquisitions (1)

Werewolf Therapeutics’s most recent deal was a Reverse Merger with Ambros Therapeutics. The deal was made on 21-Aug-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ambros Therapeutics 21-Aug-2026 Reverse Merger Biotechnology
To view Werewolf Therapeutics’s complete acquisitions history, request access »

Werewolf Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

41.35 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Werewolf Therapeutics’s complete esg history, request access »

Werewolf Therapeutics FAQs

  • When was Werewolf Therapeutics founded?

    Werewolf Therapeutics was founded in 2017.

  • Where is Werewolf Therapeutics headquartered?

    Werewolf Therapeutics is headquartered in Waltham, MA.

  • What is the size of Werewolf Therapeutics?

    Werewolf Therapeutics has 14 total employees.

  • What industry is Werewolf Therapeutics in?

    Werewolf Therapeutics’s primary industry is Drug Discovery.

  • Is Werewolf Therapeutics a private or public company?

    Werewolf Therapeutics is a Public company.

  • What is Werewolf Therapeutics’s stock symbol?

    The ticker symbol for Werewolf Therapeutics is HOWL.

  • What is the current stock price of Werewolf Therapeutics?

    As of 20-Nov-2026 the stock price of Werewolf Therapeutics is $0.94.

  • What is the current market cap of Werewolf Therapeutics?

    The current market capitalization of Werewolf Therapeutics is $46M.

  • What is Werewolf Therapeutics’s current revenue?

    The trailing twelve month revenue for Werewolf Therapeutics is $21M.

  • Who are Werewolf Therapeutics’s competitors?

    PMV Pharma, Xilio Therapeutics, Immunocore Holdings, Nektar Therapeutics, and Centrose are some of the 6 competitors of Werewolf Therapeutics.

  • What is Werewolf Therapeutics’s annual earnings per share (EPS)?

    Werewolf Therapeutics’s EPS for 12 months was -$0.58.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process